Angela Schwab, founder and CEO of Trialynx, discusses the current state of AI in the pharmaceutical industry and why it’s ...

Alnylam Pharmaceuticals has announced a $250 million investment to expand its manufacturing facility in Massachusetts. The ...

Amgen’s acquisition of Dark Blue Therapeutics adds a first-in-class leukemia program that aligns with the company’s growing ...

Nimbus Therapeutics announced it has entered into a multi-year research collaboration and $1.3 exclusive license agreement ...

In the absence of clear regulatory standards, oversight is increasingly being defined through audits, investigations, and enforcement actions by federal regulators and state medical boards rather than ...

Humans also create value through ethical restraint, the ability to recognize when not to cut corners, when to delay, and when to prioritize patient safety or scientific rigor over speed. That human ...

Ketamine's rapid antidepressant effects have led to a significant increase in off-label psychiatric use, despite the lack of ...

Novo Nordisk's Wegovy® pill, the first and only oral GLP-1 for weight loss in adults, now broadly available across America ...

The collaboration with Sanofi focuses on developing bispecific antibodies for autoimmune diseases, leveraging predictive ...

Capital allocation depends heavily on perceived stability. Brand Finance analysis of US companies shows stronger brand ...

In today’s Pharmaceutical Executive Daily, the Wegovy Pill becomes the first available oral GLP-1 for weight management, ...

As has been the case for the past several years, industry experts will be focused on Merck at the 44 th Annual JP Morgan ...